Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

C-3- and C-4-Substituted Bicyclic Coumarin Sulfamates as Potent Steroid Sulfatase Inhibitors.

Ganeshapillai D, Woo LWL, Thomas MP, Purohit A, Potter BVL.

ACS Omega. 2018 Sep 30;3(9):10748-10772. doi: 10.1021/acsomega.8b01383. Epub 2018 Sep 6.

2.

Synthesis and structure-activity relationship studies of derivatives of the dual aromatase-sulfatase inhibitor 4-{[(4-cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate.

Woo LW, Wood PM, Bubert C, Thomas MP, Purohit A, Potter BV.

ChemMedChem. 2013 May;8(5):779-99. doi: 10.1002/cmdc.201300015. Epub 2013 Mar 11.

3.

Structure-activity relationship for the first-in-class clinical steroid sulfatase inhibitor Irosustat (STX64, BN83495).

Woo LW, Ganeshapillai D, Thomas MP, Sutcliffe OB, Malini B, Mahon MF, Purohit A, Potter BV.

ChemMedChem. 2011 Nov 4;6(11):2019-34. doi: 10.1002/cmdc.201100288. Epub 2011 Aug 25.

4.

Steroid sulfatase: a pivotal player in estrogen synthesis and metabolism.

Purohit A, Woo LW, Potter BV.

Mol Cell Endocrinol. 2011 Jul 4;340(2):154-60. doi: 10.1016/j.mce.2011.06.012. Epub 2011 Jun 30. Review.

PMID:
21693170
5.

Aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole and vorozole templates.

Wood PM, Woo LW, Thomas MP, Mahon MF, Purohit A, Potter BV.

ChemMedChem. 2011 Aug 1;6(8):1423-38. doi: 10.1002/cmdc.201100145. Epub 2011 May 23.

6.

Hybrid dual aromatase-steroid sulfatase inhibitors with exquisite picomolar inhibitory activity.

Woo LW, Bubert C, Purohit A, Potter BV.

ACS Med Chem Lett. 2010 Dec 29;2(3):243-7. doi: 10.1021/ml100273k. eCollection 2011 Mar 10.

7.

Development of steroid sulfatase inhibitors.

Woo LW, Purohit A, Potter BV.

Mol Cell Endocrinol. 2011 Jul 4;340(2):175-85. doi: 10.1016/j.mce.2010.12.035. Epub 2011 Jan 14. Review.

PMID:
21238537
8.

Bicyclic derivatives of the potent dual aromatase-steroid sulfatase inhibitor 2-bromo-4-{[(4-cyanophenyl)(4h-1,2,4-triazol-4-yl)amino]methyl}phenylsulfamate: synthesis, SAR, crystal structure, and in vitro and in vivo activities.

Wood PM, Woo LW, Labrosse JR, Thomas MP, Mahon MF, Chander SK, Purohit A, Reed MJ, Potter BV.

ChemMedChem. 2010 Sep 3;5(9):1577-93. doi: 10.1002/cmdc.201000203.

PMID:
20632362
9.

Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template.

Woo LW, Jackson T, Putey A, Cozier G, Leonard P, Acharya KR, Chander SK, Purohit A, Reed MJ, Potter BV.

J Med Chem. 2010 Mar 11;53(5):2155-70. doi: 10.1021/jm901705h.

PMID:
20148564
10.

The development of steroid sulfatase inhibitors for hormone-dependent cancer therapy.

Day JM, Purohit A, Tutill HJ, Foster PA, Woo LW, Potter BV, Reed MJ.

Ann N Y Acad Sci. 2009 Feb;1155:80-7. doi: 10.1111/j.1749-6632.2008.03677.x. Review.

PMID:
19250195
11.

Determination of the absolute configuration of aromatase and dual aromatase-sulfatase inhibitors by vibrational and electronic circular dichroism spectra analysis.

Abbate S, Longhi G, Castiglioni E, Lebon F, Wood PM, Woo LW, Potter BV.

Chirality. 2009 Oct;21(9):802-8. doi: 10.1002/chir.20685.

PMID:
19161217
12.

Inhibition of steroid sulfatase activity in endometriotic implants by STX64 (667Coumate): a potential new therapy.

Fusi L, Purohit A, Brosens J, Woo LW, Potter BV, Reed MJ.

ScientificWorldJournal. 2008 Dec 25;8:1325-7. doi: 10.1100/tsw.2008.164.

13.

A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor.

Foster PA, Chander SK, Newman SP, Woo LW, Sutcliffe OB, Bubert C, Zhou D, Chen S, Potter BV, Reed MJ, Purohit A.

Clin Cancer Res. 2008 Oct 15;14(20):6469-77. doi: 10.1158/1078-0432.CCR-08-1027.

14.

Synthesis of aromatase inhibitors and dual aromatase steroid sulfatase inhibitors by linking an arylsulfamate motif to 4-(4H-1,2,4-triazol-4-ylamino)benzonitrile: SAR, crystal structures, in vitro and in vivo activities.

Bubert C, Woo LW, Sutcliffe OB, Mahon MF, Chander SK, Purohit A, Reed MJ, Potter BV.

ChemMedChem. 2008 Nov;3(11):1708-30. doi: 10.1002/cmdc.200800164.

PMID:
18816537
15.

Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography.

Woo LW, Fischer DS, Sharland CM, Trusselle M, Foster PA, Chander SK, Di Fiore A, Supuran CT, De Simone G, Purohit A, Reed MJ, Potter BV.

Mol Cancer Ther. 2008 Aug;7(8):2435-44. doi: 10.1158/1535-7163.MCT-08-0195.

16.

Inhibition of steroid sulphatase activity via the percutaneous route: a new option for breast cancer therapy.

Purohit A, Chander SK, Woo LW, Parsons MF, Jhalli R, Potter BV, Reed MJ.

Anticancer Res. 2008 May-Jun;28(3A):1517-23.

17.

Chiral aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole template: synthesis, absolute configuration, and in vitro activity.

Wood PM, Woo LW, Labrosse JR, Trusselle MN, Abbate S, Longhi G, Castiglioni E, Lebon F, Purohit A, Reed MJ, Potter BV.

J Med Chem. 2008 Jul 24;51(14):4226-38. doi: 10.1021/jm800168s. Epub 2008 Jul 1.

PMID:
18590272
18.

The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer.

Foster PA, Woo LW, Potter BV, Reed MJ, Purohit A.

Endocrinology. 2008 Aug;149(8):4035-42. doi: 10.1210/en.2008-0223. Epub 2008 May 1.

19.

Direct evidence for ArO-S bond cleavage upon inactivation of Pseudomonas aeruginosa arylsulfatase by aryl sulfamates.

Bojarov√° P, Denehy E, Walker I, Loft K, De Souza DP, Woo LW, Potter BV, McConville MJ, Williams SJ.

Chembiochem. 2008 Mar 3;9(4):613-23. doi: 10.1002/cbic.200700579.

PMID:
18288656
20.

Non-steroidal aromatase inhibitors based on a biphenyl scaffold: synthesis, in vitro SAR, and molecular modelling.

Jackson T, Woo LW, Trusselle MN, Purohit A, Reed MJ, Potter BV.

ChemMedChem. 2008 Apr;3(4):603-18. doi: 10.1002/cmdc.200700266.

PMID:
18236493
21.

Inhibition of steroid sulphatase activity in endometriotic implants by 667 COUMATE: a potential new therapy.

Purohit A, Fusi L, Brosens J, Woo LW, Potter BV, Reed MJ.

Hum Reprod. 2008 Feb;23(2):290-7. Epub 2007 Dec 2.

PMID:
18056119
22.

Dual aromatase-sulfatase inhibitors based on the anastrozole template: synthesis, in vitro SAR, molecular modelling and in vivo activity.

Jackson T, Woo LW, Trusselle MN, Chander SK, Purohit A, Reed MJ, Potter BV.

Org Biomol Chem. 2007 Oct 21;5(20):2940-52.

PMID:
17972413
23.

Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer.

Foster PA, Chander SK, Parsons MF, Newman SP, Woo LW, Potter BV, Reed MJ, Purohit A.

Breast Cancer Res Treat. 2008 Sep;111(1):129-38. Epub 2007 Oct 4.

PMID:
17914670
24.

Dual aromatase-sulfatase inhibitors based on the anastrozole template: synthesis, in vitro SAR, molecular modelling and in vivo activity.

Jackson T, Woo LW, Trusselle MN, Chander SK, Purohit A, Reed MJ, Potter BV.

Org Biomol Chem. 2007 Sep 21;5(18):2940-52. Epub 2007 Aug 7. Erratum in: Org Biomol Chem. 2007 Oct 21;5(20):3368. Corrected and republished in: Org Biomol Chem. 2007 Oct 21;5(20):2940-52.

PMID:
17728860
25.

Dual aromatase-steroid sulfatase inhibitors.

Woo LW, Bubert C, Sutcliffe OB, Smith A, Chander SK, Mahon MF, Purohit A, Reed MJ, Potter BV.

J Med Chem. 2007 Jul 26;50(15):3540-60. Epub 2007 Jun 20.

PMID:
17580845
26.

Steroid sulfatase: a new target for the endocrine therapy of breast cancer.

Stanway SJ, Delavault P, Purohit A, Woo LW, Thurieau C, Potter BV, Reed MJ.

Oncologist. 2007 Apr;12(4):370-4. Review.

27.

Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor.

Stanway SJ, Purohit A, Woo LW, Sufi S, Vigushin D, Ward R, Wilson RH, Stanczyk FZ, Dobbs N, Kulinskaya E, Elliott M, Potter BV, Reed MJ, Coombes RC.

Clin Cancer Res. 2006 Mar 1;12(5):1585-92.

28.

First crystal structures of human carbonic anhydrase II in complex with dual aromatase-steroid sulfatase inhibitors.

Lloyd MD, Thiyagarajan N, Ho YT, Woo LW, Sutcliffe OB, Purohit A, Reed MJ, Acharya KR, Potter BV.

Biochemistry. 2005 May 10;44(18):6858-66.

PMID:
15865431
29.

A letrozole-based dual aromatase-sulphatase inhibitor with in vivo activity.

Wood PM, Woo LW, Humphreys A, Chander SK, Purohit A, Reed MJ, Potter BV.

J Steroid Biochem Mol Biol. 2005 Feb;94(1-3):123-30. Epub 2005 Feb 5.

PMID:
15862957
30.

Steroid sulfatase: molecular biology, regulation, and inhibition.

Reed MJ, Purohit A, Woo LW, Newman SP, Potter BV.

Endocr Rev. 2005 Apr;26(2):171-202. Epub 2004 Nov 23. Review.

PMID:
15561802
31.

Crystal structure of human carbonic anhydrase II at 1.95 A resolution in complex with 667-coumate, a novel anti-cancer agent.

Lloyd MD, Pederick RL, Natesh R, Woo LW, Purohit A, Reed MJ, Acharya KR, Potter BV.

Biochem J. 2005 Feb 1;385(Pt 3):715-20.

32.

Pharmacokinetics of the nonsteroidal steroid sulphatase inhibitor 667 COUMATE and its sequestration into red blood cells in rats.

Ireson CR, Chander SK, Purohit A, Parish DC, Woo LW, Potter BV, Reed MJ.

Br J Cancer. 2004 Oct 4;91(7):1399-404.

33.

The role of steroid sulphatase in regulating the oestrogenicity of oestrogen sulphamates.

Chander SK, Purohit A, Woo LW, Potter BV, Reed MJ.

Biochem Biophys Res Commun. 2004 Sep 10;322(1):217-22.

PMID:
15313194
34.

Synthesis, in vitro and in vivo activity of benzophenone-based inhibitors of steroid sulfatase.

Hejaz HA, Woo LW, Purohit A, Reed MJ, Potter BV.

Bioorg Med Chem. 2004 May 15;12(10):2759-72.

PMID:
15110857
35.

2-difluoromethyloestrone 3-O-sulphamate, a highly potent steroid sulphatase inhibitor.

Reed JE, Woo LW, Robinson JJ, Leblond B, Leese MP, Purohit A, Reed MJ, Potter BV.

Biochem Biophys Res Commun. 2004 Apr 23;317(1):169-75.

PMID:
15047163
36.

Steroid sulphatase inhibitors for breast cancer therapy.

Purohit A, Woo LW, Chander SK, Newman SP, Ireson C, Ho Y, Grasso A, Leese MP, Potter BV, Reed MJ.

J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):423-32. Review.

PMID:
14623540
37.

First dual aromatase-steroid sulfatase inhibitors.

Woo LW, Sutcliffe OB, Bubert C, Grasso A, Chander SK, Purohit A, Reed MJ, Potter BV.

J Med Chem. 2003 Jul 17;46(15):3193-6.

PMID:
12852749
38.

Inhibition of carbonic anhydrase II by steroidal and non-steroidal sulphamates.

Ho YT, Purohit A, Vicker N, Newman SP, Robinson JJ, Leese MP, Ganeshapillai D, Woo LW, Potter BV, Reed MJ.

Biochem Biophys Res Commun. 2003 Jun 13;305(4):909-14.

PMID:
12767917
39.

Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase activity by 2-methoxyoestradiol-bis-sulphamate.

Raobaikady B, Purohit A, Chander SK, Woo LW, Leese MP, Potter BV, Reed MJ.

J Steroid Biochem Mol Biol. 2003 Feb;84(2-3):351-8.

PMID:
12711022
40.

Novel D-ring modified steroid derivatives as potent, non-estrogenic, steroid sulfatase inhibitors with in vivo activity.

Fischer DS, Chander SK, Woo LW, Fenton JC, Purohit A, Reed MJ, Potter BV.

J Steroid Biochem Mol Biol. 2003 Feb;84(2-3):343-9.

PMID:
12711021
41.

Development of a sensitive high-performance liquid chromatography method for the detection of 667 COUMATE in vivo.

Ireson CR, Parish D, Purohit A, Woo LW, Potter BV, Chander SK, Reed MJ.

J Steroid Biochem Mol Biol. 2003 Feb;84(2-3):337-42.

PMID:
12711020
42.

D-ring modified estrone derivatives as novel potent inhibitors of steroid sulfatase.

Fischer DS, Woo LW, Mahon MF, Purohit A, Reed MJ, Potter BV.

Bioorg Med Chem. 2003 Apr 17;11(8):1685-700.

PMID:
12659755
43.

Inhibition of superoxide dismutase by 2-methoxyoestradiol analogues and oestrogen derivatives: structure-activity relationships.

Wood L, Leese MR, Leblond B, Woo LW, Ganeshapillai D, Purohit A, Reed MJ, Potter BV, Packham G.

Anticancer Drug Des. 2001 Aug-Oct;16(4-5):209-15.

PMID:
12049479
44.

Inhibition of steroid sulphatase activity by tricyclic coumarin sulphamates.

Malini B, Purohit A, Ganeshapillai D, Woo LW, Potter BV, Reed MJ.

J Steroid Biochem Mol Biol. 2000 Dec 31;75(4-5):253-8.

PMID:
11282279
45.

Non-steroidal and steroidal sulfamates: new drugs for cancer therapy.

Purohit A, Woo LW, Barrow D, Hejaz HA, Nicholson RI, Potter BV, Reed MJ.

Mol Cell Endocrinol. 2001 Jan 22;171(1-2):129-35.

PMID:
11165021
46.
47.

Recent advances in the development of steroid sulphatase inhibitors.

Purohit A, Hejaz HA, Woo LW, van Strien AE, Potter BV, Reed MJ.

J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):227-38.

PMID:
10418996
48.

The development of A-ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity.

Purohit A, Vernon KA, Hummelinck AE, Woo LW, Hejaz HA, Potter BV, Reed MJ.

J Steroid Biochem Mol Biol. 1998 Mar;64(5-6):269-75.

PMID:
9618028
49.

Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase.

Woo LW, Howarth NM, Purohit A, Hejaz HA, Reed MJ, Potter BV.

J Med Chem. 1998 Mar 26;41(7):1068-83.

PMID:
9544207
50.

In vivo activity of 4-methylcoumarin-7-O-sulfamate, a nonsteroidal, nonestrogenic steroid sulfatase inhibitor.

Purohit A, Woo LW, Singh A, Winterborn CJ, Potter BV, Reed MJ.

Cancer Res. 1996 Nov 1;56(21):4950-5.

Supplemental Content

Support Center